Mitogenic effect of lipoproteins on human vascular smooth muscle cells: The impact of hydrolysis by gr II a phospholipase A2

Laboratory Investigation

Volumn 81, Issue 5, 2001, Pages 757-765

  Pruzanski, Waldemar ^a,b   Stefanski, Eva ^a   Kopilov, Julia ^a   Kuksis, Amis ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; FATTY ACID; HIGH DENSITY LIPOPROTEIN; LINOLEIC ACID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LYSOPHOSPHATIDYLCHOLINE; OLEIC ACID; PHOSPHOLIPASE A2;

ARTICLE; ATHEROGENESIS; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; HYDROLYSIS; MITOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; VASCULAR SMOOTH MUSCLE;

EID: 0035005669     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1038/labinvest.3780284     Document Type: Article

References (66)

1. 2: Molecular cloning, identification of a secreted soluble form, expression, and chromosomal localization. J Biol Chem 270:8963-8970.
2. 2-mediated release of arachidonic acid is critical for proliferation of vascular smooth muscle cells. J Biol Chem 272: 30504-30511.
3. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, and La Du BN (1998). Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions: A possible peroxidative role for paraoxonase. J Clin Invest 101:1581-1590.
4. Badolato R, Wang JM, Murphy WJ, Lloyd AR, Michiel DF, Bausserman LL, Kelvin DJ, and Oppenheim JJ (1994). Serum amyloid A is a chemoattractant: Induction of migration, adhesion and tissue infiltration of monocytes and polymorphonuclear leukocytes. J Exp Med 180:203-209.
5. Bandyopadhyay GK, Imagawa W, Wallace D, and Nandi S (1987). Linoleate metabolites enhance the in vitro proliferative response of mouse mammary epithelial cells to epidermal growth factor. J Biol Chem 262:2750-2756.
6. Baumann H and Gauldie J (1994). The acute phase response. Immunol Today 15:74-80.
7. Bruce IN, Gladman DD, and Urowitz MB (1998). Detection and modification of risk factors for coronary artery disease in patients with systemic lupus erythematosus: A quality improvement study. Clin Exp Rheumatol 15:435-440.
8. Castellani LW, Navab M, Lenten BJV, Hedrick CC, Hama SY, Goto AM, Fogelman AM, and Lusis AJ (1997). Overexpression of apolipoprotein all in transgenic mice converts high density lipoproteins to proinflammatory particles. J Clin Invest 100:464-474.
9. Chen J-K, Hoshi H, McClure DB, and McKeehan WL (1986). Role of lipoproteins in growth of human adult arterial endothelial and smooth muscle cells in low lipoprotein-deficient serum. J Cell Physiol 129:207-214.
10. Daugherty A (1997). Atherosclerosis: Cell biology and lipoproteins. Curr Opin Lipidol 8:U11-U12.
11. de Beer FC, Fagan EA, Hughes GRV, Mallya RK, Lanham JG, and Pepys MB (1982). Serum amyloid-A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet II:231-237.
12. Fang X, Gibson S, Flowers M, Furui T, Bast RC Jr, and Mills GB (1997). Lysophosphatidylcholine stimulates activator protein 1 and c-Jun N-terminal kinase activity. J Biol Chem 272:13683-13689.
13. Gaumond F, Fortin D, Stankova J, and Rola-Pleszczynski M (1997). Different signaling pathways in platelet-activating factor-induced proliferation and interleukin-6 production by rat vascular smooth muscle cells. J Cardiovasc Pharmacol 30:169-175.
14. Hajjar DP and Pomerantz KB (1992). Signal transduction in atherosclerosis: Integration of cytokines and the eicosanoid network. FASEB J 6:2933-2941.
15. Hansson GK, Jonasson L, Seifert PS, and Stemme S (1989). Immune mechanisms in atherosclerosis. Atherosclerosis 9:567-578.
16. Heery JM, Kozak M, Stafforini DM, Jones DA, Zimmerman GA, McIntyre TM, and Prescott SM (1995). Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates growth of smooth muscle cells. J Clin Invest 96:2322-2330.
17. Herbert JM, Laplace MC, Mares AM, and Dol F (1995). Platelet-activating factor (PAF) is not an essential component of the cascade leading to smooth muscle cell proliferation following vascular injury. J Lipid Mediat Cell Signal 12:49-57.
18. 2 in normal and atherosclerotic arteries: Activity of the isolated enzyme on low-density lipoproteins. Arterioscler Thromb Vasc Biol 17: 300-309.
19. 2. Arterioscler Thromb Vasc Biol 19:1284-1290.
20. Kaneko T, Baba N, and Matsuo M (1996). Cytotoxicity of phosphatidylcholine hydroperoxides is exerted through decomposition of fatty acid hydroperoxide moiety. Free Radic Biol Med 21:173-179.
21. Keler T, Barker CS, and Sorof S (1992). Specific growth stimulation by linoleic acid in hepatoma cell lines transfected with the target protein of a liver carcinogen. Proc Natl Acad Sci USA 89:4830-4834.
22. Kisilevsky R and Subrahmanyan L (1992). Serum amyloid A changes high density lipoprotein's cellular affinity. A clue to serum amyloid A's principal function. Lab Invest 66:778-785.
23. Kol A, Bourcier T, Lichtman AH, and Libby P (1999). Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J Clin Invest 103:571-577.
24. Kume N, Cybulsky MI, and Gimbrone MA Jr (1992). Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endotheial cells. J Clin Invest 90:1138-1144.
25. 2 in atherosclerosis. 2. Potential involvement of biologically active oxidized phospholipids. Arterioscler Thromb Vasc Biol 19:1291-1298.
26. Libby P, Sukhova B Lee RT, and Liao JK (1997). Molecular biology of atherosclerosis, Int J Cardiol 2:S23-S29.
27. Libby P, Miao P, Ordovas JM, and Schaefer EJ (1985). Lipoproteins increase growth of mitogen-stimulated arterial smooth muscle cells. J Cell Physiol 124:1-8.
28. 2 as an index of disease activity in rheumatoid arthritis: Prospective double blind study of 212 patients. J Rheumatol 23:1162-1166.
29. Locher R, Weisser B, Mengden T, Brunner C, and Vetter W (1992). Lysolecithin actions on vascular smooth muscle cells. Biochem Biophys Res Commun 183:156-162.
30. Loppnow H and Libby P (1990). Proliferating or interleukin 1-activated human vascular smooth muscle cells secrete copious interleukin 6. J Clin Invest 85:731-738.
31. Malle E, Steinmetz A, and Raynes JG (1993). Serum amyloid A (SAA): An acute phase protein and apolipoprotein. Atherosclerosis 102:131-146.
32. Nabata T, Morimoto S, Koh E, Shiraishi T, and Ogihara T (1990). Interleukin-6 stimulates c-myc expression and proliferation of cultured vascular smooth muscle cells. Biochem Int 20:445-453.
33. Navab M, Hama SY, Hough GP, Hedrick CC, Sorenson R, La Du BN, Kobashigawa JA, Fonarrow GC, Berliner JA, Laks H, and Fogelman AM (1998). High density associated enzymes: Their role in vascular biology. Curr Opin Lipidol 9:449-456.
34. Nilsson J (1993). Cytokines and smooth muscle cells in atherosclerosis. Cardiovasc Res 27:1184-1190.
35. Parthasarathy S and Barnett J (1990). Phospholipase A2 activity of low density lipoprotein: Evidence for an intrinsic phospholipase A2 activity of apoprotein B-100. Proc Natl Acad Sci USA 87:9741-9745.
36. Parthasarathy S, Barnett J, and Fong LG (1990). High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1044:275-283.
37. 2 synthesis by plasma high and low density lipoproteins. Circ Res 54:554-565.
38. 2. Biochem J 309:461-464.
39. 2 activity and antilipocortin antibodies in systemic lupus erythematosus: Correlative study with disease activity. J Rheumatol 21:252-257.
40. Pruzanski W, Stefanski E, de Beer FC, de Beer MC, Ravandi A, and Kuksis A (2000). Comparative analysis of lipid composition of normal and acute phase high density lipoproteins. J Lipid Res 41:1035-1047.
41. 2: Preferential hydrolysis of acute phase HDL J Lipid Res 39:2150-2160.
42. 2: Role in physiologic and inflammatory processes. J Lipid Med 8:161-167.
43. Quinn MT, Parthasarathy S, and Steinberg D (1988). Lysophosphatidylcholine: A chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci USA 85:2805-2809.
44. Raines EW and Ross R (1993). Smooth muscle cells and the pathogenesis of the lesions of atherosclerosis. Br Heart J 69:S30-S37.
45. Rao GN, Alexander RW, and Runge MS (1995). Linoleic acid and its metabolites, hydroxyoctadecadienoic acids, stimulate c-Fos, c-Jun and c-Myc mRNA expression, mitogen-activated protein kinase activation, and growth in rat aortic smooth muscle cells. J Clin Invest 96:842-847.
46. Robenek H and Severs NJ (1993). Lipoprotein receptors on macrophages and smooth muscle cells. Curr Top Pathol 87:73-123.
47. 2 in atherosclerotic and nonatherosclerotic regions of human arteries. Arterioscler Thromb Vasc Biol 18:519-525.
48. Rosenberg RD and Simons M (1996). Vascular smooth-muscle-cell proliferation: Basic investigations and new therapeutic approaches. In: Mockrin SC, editor. Molecular genetics and gene therapy of cardiovascular disease. New York: Marcel Dekker, 547-581.
49. 2 type II binds to extracellular matrix biglycan: Modulation of its activity on LDL by colocalization in glycosaminoglycan matrixes. Arterioscler Thromb Vasc Biol 18:1934-1941.
50. Scott-Burden T, Resink TJ, Hahn AWA, Baur U, Box RJ, and Buhler FR (1989). Induction of growth-related metabolism in human vascular smooth muscle cells by low density lipoprotein. J Biol Chem 264:12582-12589.
51. Shephard EG, de Beer FC, de Beer MC, Jeenah MS, Coetzee GA, and van der Westhuyzen DR (1987). Neutrophil association and degradation of normal and acute-phase high-density lipoprotein 3. Biochem J 248:919-926.
52. Steel DM and Whitehead AS (1994). The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein, Immunol Today 15:81-88.
53. Stein O and Stein Y (1995). Smooth muscle cells and atherosclerosis. Curr Opin Lipidol 6:269-274.
54. Steinberg D and Witztum JL (1990). Lipoproteins and atherogenesis: Current concepts. JAMA 264:3047-3052.
55. Steinbrecher UP and Pritchard PH (1989). Hydrolysis of phosphatidylcholine during LDL oxidation is mediated by platelet-activating factor acetylhydrolase. J Lipid Res 30: 305-315.
56. Su BSB, Gong W, Gao J-L, Shen W, Murphy PM, Oppenheim JJ, and Wang JM (1999). A seven-transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J Exp Med 189:395-402.
57. Sugatani J, Miwa M. Komiyama Y, and Ito S (1996). High-density lipoprotein inhibits the synthesis of platelet-activating factor in human vascular endothelial cells. J Lipid Mediat Cell Signal 13:73-88.
58. Tall AR (1990). Plasma high density lipoproteins: Metabolism and relationship to atherogenesis. J Clin Invest 86:379-384.
59. Urowitz MB and Gladman DD (1999). Evolving spectrum of mortality and morbidity in SLE. Lupus 8:253-255.
60. 2 espression and inflammation: The relationship with associated disease states. J Lipid Mediat 8:1-30.
61. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La Du BN, Fogelman AM, and Navab M (1995). Anti-inflammatory HDL becomes proinflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 96:2758-2767.
62. Wang T and Powell WS (1991). Increased levels of monohydroxy metabolites of arachidonic acid and linoleic acid in LDL and aorta from atherosclerotic rabbits. Biochem Biophys Acta 1084:129-138.
63. Wick G, Romen M, Amberger A, Metzler B, Mayr M, Falkensammer G, and Xu Q (1997). Atherosclerosis, autoimmunity, and vascular-associated lymphoid tissue (Review). FASEB J 11:1199-1207.
64. Wick G, Schett G, Amberger A, Kleindienst R, and Xu Q (1995). Is atherosclerosis an immunologically mediated disease? Immunol Today 16:27-33.
65. Yagi K, Komura S, Kojima H, Sun Q, Nagata N, Ohishi N, and Nishikimi M (1996). Expression of human phospholipid hydroperoxide glutathione peroxidase gene for protection of host cells from lipid hydroperoxide-mediated injury. Biochem Biophys Res Commun 219:486-491.
66. Yamakawa T, Eguchi S, Yamakawa Y, Motley ED, Numaguchi K, Utsunomiya H, and Inagami T (1998). Lysophosphatidylcholine stimulates MAP kinase activity in rat vascular smooth muscle cells. Hypertension 31:248-253.